SOPHiA GENETICS SA (SOPH) has been on a downward spiral lately with significant selling pressure. After declining 30.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

SOPHiA GENETICS SA (SOPH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Individual inv ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer. Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Tejas Savant - Morgan Stanley Operator Good morning. My name is Kevin and I'll be your conference operator ...

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 17.86%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%. Over the last four quarters, the company has surpas ...

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | | Unaudited Interim Condensed Consolidated Financial Statements | | – | Unaudited Interim Condensed Consolidated Statements of Loss | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss Unaudited Interim Condensed Consolidated Balance Sheets | | ...

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland, Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-ov ...

BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders. "As a research and teaching hospital, as well as a clinical center of excellence, it is our goal to ...

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland, July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for ...

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its genomic and molecular testing capabilities [1][8] - The partnership with the Hematology Translational Lab at the University of Calgary has significantly advanced precision oncology and immunology research [1] - Liquid biopsy testing, which extracts cell-free DNA from blood plasma, offers a less invasive alternative to traditional biopsies, facilitating quicker clinical decisions and monitoring [2][9] Company Developments - OncoHelix will utilize the new liquid biopsy solution to enhance its oncology testing capabilities, building on its existing use of the SOPHiA DDM™ Platform for myeloid testing [8][9] - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, focusing on deep sequencing of 146 cancer-associated genes [9] - The implementation of this technology is expected to improve the assessment of cancer treatment responses and the diagnosis of cases where tissue biopsy is not feasible [3][9] Industry Context - SOPHiA GENETICS is a leader in data-driven medicine, utilizing AI to provide actionable insights for healthcare institutions globally [5] - The collaboration between OncoHelix and SOPHiA GENETICS reflects a growing trend in the healthcare industry towards integrating advanced genomic technologies to improve patient care [9]

BOSTON and ROLLE, Switzerland, July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year 2024 before U.S. markets open on Tuesday, August 6, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webc ...